P-086 YI Natalizumab for Moderate to Severe Crohnʼs Disease
نویسندگان
چکیده
منابع مشابه
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
BACKGROUND Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer'...
متن کاملLiver impairment among neonates with moderate to severe asphyxia
Background and Objectives: Perinatal asphyxia may cause severe damages in different organs such as kidneys, lungs, liver and most importantly CNS. The current study aimed to evaluate and compare the prevalence of liver impairment among asphyxiated and normal neonates. Methods: A retrospective case-control study was carried out in a referral pediatrics Hospital (Iran- from 2013 to 2015). Term an...
متن کاملClinical evaluation of patients with moderate to severe Alzheimer disease
Today, Alzheimer disease has become a serious risk to individual and public health, due to the significant incapacity it causes patients, its influence on family members and caregivers, along with the ensuing direct and indirect costs. Objectives To build the profile of patients with moderate/severe AD, in the Geriatric Clinic Service of Cognitive Alterations of the Medical School at Universi...
متن کاملSevere Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for further study.
متن کاملTreatment Approaches to Moderate to Severe Psoriasis
Psoriasis is a common disease, which has a considerable impact on patients and the health care system. Treatment approaches to the disease may be various because some issues are not definitely addressed. Moreover, the therapeutic paradigms are continuously changing because of the recent approval of new treatments for psoriasis such as interleukin (IL)-17 inhibitors and apremilast. In this revie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammatory Bowel Diseases
سال: 2014
ISSN: 1078-0998
DOI: 10.1097/01.mib.0000456825.46020.d8